Miki Fukutani

Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)

Kohei Shitara, Toshihiko Doi, Osamu Nagano et al. · Gastric Cancer · 2016 · 103 citations · Full text

Medicine, Oncology, Pharmacology +16

TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)

Akihito Kawazoe, Kota Itahashi, Noboru Yamamoto et al. · Clinical Cancer Research · 2021 · 70 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)

Kohei Shitara, Toshihiko Doi, Osamu Nagano et al. · Gastric Cancer · 2017 · 59 citations · Full text

Medicine, Oncology, Pharmacology +8

TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma

Hideaki Bando, Daisuke Kotani, Takahiro Tsushima et al. · BMC Cancer · 2020 · 53 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).

Keiju Aokage, Yoshihisa Shimada, Kiyotaka Yoh et al. · Journal of Clinical Oncology · 2023 · 18 citations

Pharmacy, Pharmacotherapy, Cancer Immunology +16